For the Inventor, By the Inventor

Enter inventor name

Alpine, UT, United States of America

David J Bearss

USPTO Granted Patents = 50 (Patent Applications = 27)

CIPO Patents = 2 (Patent Applications = 13)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 4.1

ph-index = 14

Forward Citations = 563(Granted Patents)

Forward Citations (Not Self Cited) = 440(Oct 12, 2025)

Location History:

Tucson, AZ (US) (2006)
Highland, UT (US) (2008)
Modesto, CA (US) (2006 - 2015)
Cedar Hills, UT (US) (2007 - 2015)
Lehi, UT (US) (2020)
Alpine, UT (US) (2013 - 2023)

Company Filing History:

Tolero Pharmaceuticals, Inc.

10 out of 1,644

University of Utah Research Foundation

4. 6 out of 972

University of Arizona

Sumitomo Pharma Oncology, Inc.

Neuropro Technologies, Inc.

Montigen Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Astex Pharmaceuticals, Inc.

Astex Pharmaceutials, Inc.

Biolexis Therapeutics, Inc.

12. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Loading Chart...

Loading Chart...

50 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12338261 - Alvocidib prodrugs having increased bioavailability (2025-06-24),

2. 12275738 - CDK9 inhibitors (2025-04-14),

3. 11793802 - Treatment of acute myeloid leukemia (AML) with venetoclax failure (2023-10-24),

4. 11712433 - Compositions comprising PKM2 modulators and methods of treatment using the same (2023-08-01),

5. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),

6. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),

7. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),

8. 11040038 - Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same (2021-06-22),

9. 10835537 - Combination therapies for treatment of cancer (2020-11-17),

10. 10752594 - JAK1 and ALK2 inhibitors and methods for their use (2020-08-25),

11. 10682356 - Combination therapies for treatment of cancer (2020-06-16),

12. 10624880 - Predicting response to alvocidib by mitochondrial profiling (2020-04-21),

13. 10568887 - Combination therapies for treatment of cancer (2020-02-25),

14. 10562925 - Alvocidib prodrugs having increased bioavailability (2020-02-18),

15. 10422788 - Profiling peptides and methods for sensitivity profiling (2019-09-24),

Title: The Innovative Journey of David J Bearss

Introduction:

David J Bearss, a talented inventor hailing from Alpine, UT (US), has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents:

David J Bearss holds several patents in various technological domains, including but not limited to software applications, electronic devices, and communication systems.

Career Highlights:

Throughout his illustrious career, David J Bearss has demonstrated a remarkable ability to transform innovative ideas into tangible inventions. His dedication to pushing the boundaries of technology has led to the development of cutting-edge solutions that have revolutionized the industry.

Collaborations:

David J Bearss has collaborated with leading tech companies, research institutions, and universities to further his research and bring his inventions to life. His collaborative spirit and passion for innovation have been instrumental in his success as an inventor.

Conclusion:

In conclusion, David J Bearss stands as a shining example of creativity and ingenuity in the world of technology. His relentless pursuit of innovation and commitment to excellence continue to inspire aspiring inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…